PRESS RELEASE
News
-
-
PRESS RELEASE
Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder
Jaguar Health, Inc. initiates Phase 2 study for crofelemer, a novel plant-based drug, in pediatric MVID patients. Study aims to evaluate drug efficacy for rare diseases MVID and SBS-IF -
-
-
PRESS RELEASE
Electrovaya Inc. Closes US$11.1 Million Public Offering of Common Shares
Electrovaya Inc. successfully closes public offering of 5,175,000 Common Shares at US$2.15 per share, grossing US$11.1 million. Proceeds to be used for loan conditions, working capital, refinancing, and manufacturing facility purchase -
-
-
PRESS RELEASE
EQS-Adhoc: AMAG Austria Metall AG: AMAG Austria Metall AG: Impairment requirement affects EBIT in FY 2024; EBITDA range remains unchanged
AMAG Austria Metall AG expects EBIT reduction in FY 2024 due to impairment charges while EBITDA range remains unchanged. Details on impairment impact and future profitability -
PRESS RELEASE
Verisante Technology, Inc. Announces RTO Update:
SunRegen Healthcare AG closes $2.1 million private placement, advancing towards RTO with Verisante. SunRegen focuses on developing neurodegenerative drugs, starting with compound SBC003. Verisante to acquire 100% interest in SunRegen, aiming to qualify as Tier 2 Life Sciences Issuer -
